Oppenheimer lowered the firm’s price target on Perspective Therapeutics to $17 from $19 and keeps an Outperform rating on the shares. The firm notes Perspective Therapeutics announced Q2 results, highlighting plans across the portfolio, including recent data presented at SNMMI for VMT-alpha-NET. CATX finished Q2 with $293M but revealed an aggressive spending plan focused on preclinical, clinical development, as well as establishing its distributed manufacturing infrastructure, Oppenheimer adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results
- Options Volatility and Implied Earnings Moves Today, August 12, 2024
- CATX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Four new option listings on July 30th
- Perspective Therapeutics to Participate at Upcoming Investor Conferences in August